Robert E. Claar

Robert E. Claar
President & CEO

Rob Claar co-founded Vorpal Technologies in 2013 to help create solutions for the drug, device and diagnostics lag and become the premier pathway into Japan for healthcare innovations.
Click here for more information
  • Vorpal is a full-service virtual subsidiary, enabling overseas healthcare innovators to enter Japan on their own terms with transparency, confidence and optionality. Vorpal delivers expert solutions in clinical development, regulatory affairs, reimbursement, quality and safety management, logistics and market development.
  • Prior to Vorpal, Rob founded Junicon K.K., a healthcare market research and strategy consulting firm. Junicon now has a global reach with offices in the US and Europe and strong affiliations in all major markets.
  • Rob has over 25 years’ experience in healthcare innovation management, opportunity assessment, strategy development and implementation. He is passionate about developing innovative solutions for access to Japan’s healthcare market.

  • Mark Campbell

    Stacy Evans, M.D., M.B.A.
    Chief Business Officer

    Stacy has over 15 years experience in global healthcare business development, new product development, market research, strategy, outcomes research, and medical affairs. He has successfully negotiated multi-billion dollar BD transactions.
    From both his consulting and pharmaceutical BD experience, he has a wide network of U.S. and EU-based biopharmaceutical companies, as well as healthcare finance professionals.
    His work experience spans across many therapeutic areas, including Orphan/Rare disease, Ophthalmology, Endocrinology/Metabolic, Oncology, and Cardiovascular.

    Click here for more information
  • Stacy graduated from McGill University in 1999, having completed a Bachelor of Science in Biochemistry and Medical Doctorate. He also graduated Magna Cum Laude from Columbia University's Executive MBA program in 2011, with a concentration in Finance
  • In 1999 after completing his M.D., Stacy moved to New York to work for various boutique consulting firms focused in the biopharmaceutical area, including running his own firm for 2 years
  • In late 2003, he was hired by Pfizer, a previous consulting client, in a medical affairs role supporting new product development. He spent 4 years focusing on growing the Ophthalmology portfolio at Pfizer, which included two Phase 2 starts. He spent seven years in BD, leading Search & Evaluation for Ophthalmology & Vaccines and then leading Transactions for the Innovative Pharma business
  • Stacy currently lives in the San Francisco Bay Area. He is fluent in English, French, and Hebrew.

  • Benjamin D. Pratt

    Benjamin D. Pratt
    General Manager of Innovation Commercialization

    Ben has commercialized and marketed best-in-class medical devices for over a decade and has expertise in strategy development, marketing and operations. His forté and personal mission is creating new businesses in Japan for the betterment of patient care
    Click here for more information
  • Early in his career, Ben was selected by Japan’s Ministry of Education, Science, Sports, and Culture to manage sister city relations and International Association programs for the city of Hatsukaichi in Hiroshima prefecture. Early work experience also included driving company-wide projects and major promotional events at Reebok Japan
  • In 2001, Ben joined Edwards Lifesciences’ Global Franchise Management as a member of the Center for Business Intelligence, providing market insight based upon primary research, focused on global market trends, development of product requirements for R&D, competitive intelligence and pricing analysis for building franchise strategies
  • Over his 13 years at Edwards Lifesciences, Ben held leadership roles encompassing strategic planning, marketing, clinical education, post market clinical evidence development, cross-functional process integration and operations. The breadth of his experience at Edwards includes leading processes for establishing new business operations in Japan, introducing new technologies to existing businesses, and maintaining market leadership for devices with top market share
  • Ben graduated The College of William & Mary in 1995 with a B.A. in International Relations - East Asian Studies. His undergraduate experience also included a year at International Christian University, Tokyo focusing on Japan Studies. Ben achieved his M.B.A. in 2002 at the University of Southern California’s Marshall School of Business, concentrating in Marketing and Entrepreneurship
  • Publication: Pratt, et al, “Calculating Arterial Pressure-Based Cardiac Output (APCO) Using a Novel Measurement and Analysis Method”. Biomed Instrum Technol 2007, 41:403-411
  • Ben lives in Tokyo with his family and is fluent in English and Japanese

  • Benjamin D. Pratt

    Lorin K. Johnson, PhD
    Advisory Board Chairman

    Dr. Johnson is a founder of Salix Pharmaceuticals, Inc. (NASDAQ: SLXP) and held senior positions in Salix prior to its recent $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX)
    Click here for more information
  • Prior to founding Salix, Dr. Johnson served as Director of Scientific Operations and Chief Scientist at California Biotechnology, Inc, (Scios, Inc), where he headed research on anti-inflammatory therapeutics targeting secretory phospholipase A2. Before joining California Biotechnology, Dr. Johnson was an Assistant Professor of Pathology at Stanford University Medical Center. Dr. Johnson received his BS and PhD in Molecular Biology from the University of Southern California and was a postdoctoral fellow at the University of California, San Francisco, researching molecular mechanisms of corticosteroid action. Dr. Johnson is the coauthor of 75 journal articles and book chapters and is the co-inventor on 18 issued patents.

  • Toshiharu Yoshioka

    Professor Katsushi Kunimoto
    Advisory Board Chairman

    Professor Kunimoto is Director of the Kunimoto Katsushi Meta Design Lab at Nagoya City University's Graduate School of Architecture & Product Design. He is a prolific and award-winning innovator in fields of aerospace, electric vehicles and medical devices. Kunimoto's fruitful collaboration with the university's medical department and hospital have led to the development of many innovations to be commercialized through Vorpal
    Click here for more information
  • Kunimoto graduated from Kanazawa College of Art with a major in industrial design, after which he joined Mitsubishi Motors Corporation
  • As Chief Designer for the original Pajero, Kunimoto's concepts ushered in a new era in vehicle design. Subsequently, his designs have been to outer space on the Space Shuttle and his ergonomic table utensils are in the permanent collection of the Chicago Museum of Science and Industry
  • Besides Nagoya City University, Kunimoto has visiting professorships at Guangdong University of Technology (China), Guangdong Kanan University of Technology (China), Xuexue Institute (Taiwan), Nagoya University, Japan Advanced Institute of Science and Technology, Osaka University and Keio University
  • He has won over 100 domestic and international design awards including the red dot design award (Essen, Germany), iF Product Design Award (Hannover, Germany), Good Design Award (Chicago, USA), Pin UP Design Silver Award (Korea), Technology of the Year (USA), Good Design Award G-Mark (Japan), Creativity 28 Competition Award of Distinction (USA), The Art Directors Club of New York Award (USA), and many more

  • Hiroyoshi Horikoshi D.V.M., Ph.D.

    Hiroyoshi Horikoshi D.V.M., Ph.D.
    Advisory Board Member

    Hiroyoshi Horikoshi's career in pharma R&D spans 4 decades in Japan and North America at Sankyo Pharma, Daiichi Sankyo and his own company, HFX Pharma. Hiro is a sought-after advisor on health policy and academic-industry collaboration in the US and Japan
    Click here for more information
  • Hiro completed his Doctor of Veterinary Medicine decree in 1966 at the Tokyo University of Agriculture & Technology and his Ph.D. in 1973 at The University of Tokyo
  • In 1973, Hiro began his 36-year career at Sankyo Pharma and then Daiichi Sankyo with a focus on Diabetes, Endocrinological Disorders and Atherosclerosis. He held R&D positions and general management positions, becoming a board member in the US and Japan, and President of the Daiichi Sankyo Research Institute (USA)
  • In 2011, Hiro founded HFX Pharma to concentrate on the development and commercialization of a novel Diabetes medication
  • Hiro works with several universities including UCSD, Nagoya University and Nippon University. He is currently advising Tokushima Prefecture on health policy for the prevention of lifestyle-related diseases
  • Hiro was the recipient of a Business Leadership Award in 2005 from the Japan Society of San Diego and Tijuana and received a Proclamation from the California Legislative Assembly in 2006. Hiro has published 60 scientific articles and has 33 US patents

  • Shuichi Matsunaga

    Shuichi Matsunaga
    Advisory Board Member

    Shuichi Matsunaga is widely recognized as a pioneer and leading authority in the Japan medical device field. His 3-decade career at Johnson & Johnson K.K. involved building successful franchises in wound management, infection prevention, low temperature sterilization, minimally invasive surgery, Diabetes care, Orthopedics and Neurosurgery
    Click here for more information
  • Shuichi graduated from Kanagawa University with a degree in Literature in 1972, after which he started his career in medical device sales
  • He joined Johnson & Johnson in 1982 and held successive posts in sales, marketing and general management, becoming the top manager in Japan and member of the Global Management Board for a number of BUs including Advanced Sterilization Projects, Ethicon EndoSurgery, LifeScan and DePuy Group. He is an innovator of creative solutions for professional education, regulatory affairs, customer relationships and distributor management
  • He was President and Representative Director of Smith & Nephew Orthopedics K.K. between 2004 and 2007, leading a turnaround of 44% sales revenue growth. During that same period, Shuichi served on the executive committee of the ACCJ, a sister trade association of AdvaMed
  • Shuichi is currently Senior Partner with One Asia Healthcare Solutions, a healthcare management consultancy. He is also a visiting professor at Tokyo Health Care University

  • Yumiko Nagatsuma

    Yumiko Nagatsuma
    Advisory Board Member

    Yumiko Nagatsuma is an investment director at 360ip, a Battelle group company. She is a 25-year veteran venture capitalist in the Life Science sector, having completed over 30 investments in US and Japanese startups. Prior to 360ip, she was a founding partner at the University of Tokyo Edge Capital (UTEC)

    Yasuhiko Hatano Ph.D.

    Yasuhiko Hatano Ph.D.
    Advisory Board Member

    Yasuhiko Hatano is an experienced intellectual property strategist and facilitator of academic-to-industry licensing and research collaborations in healthcare technology
    Click here for more information
  • Hatano completed his Ph.D. at Kyoto Institute of Technology and post-doctoral research in Zoology at Hokkaido University
  • He joined a large multinational pharmaceutical company where he was involved in clinical development. His next role was at an in vitro diagnostics company where he was involved in drug development
  • Hatano then joined an environmental bio venture where he held successive posts as Lead Researcher, Production Manager and R&D Manager
  • In 2007 he joined Chubu Technology Licensing Office where he leads the identification of promising life science technologies in universities, licensing to corporations, organization of new ventures and coordination of joint R&D programs

  • Don Rindell

    Don Rindell
    Advisory Board Member

    Don Rindell has more than 25 years of senior executive experience in the life sciences industry. He has held executive roles in global corporate development, business development and device/technology strategy for several US and European pharmaceutical and medical device companies
    Click here for more information
  • Mr. Rindell is currently Managing Director of Camino International, LLC, a consulting practice for Business and Product Development for drug delivery therapeutics and medical devices. He most recently served as Senior Director of Corporate Development at Amylin Pharmaceuticals, which was purchased by Bristol Myers Squibb. At Amylin, he led a number of key global transactions with partners including Shionogi Pharmaceuticals, BIOCON, Takeda Pharmaceuticals and selected device delivery companies. He also provided senior management leadership to the Amylin Drug Delivery/Device Team. He has previously held senior executive positions at CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, Hybritech, and Syntex
  • Mr. Rindell is a member of the Board of Directors of publicly traded TearLab (NASDAQ: TEAR), and advisor to two other medical device companies
  • Mr. Rindell received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business

  • Jeff Cocagne

    Jeff Cocagne
    Advisory Board Member

    Jeff is a US-based marketing research and consulting veteran with 20 years experience in medical equipment and devices, pharmaceuticals and biotechnology. Jeff earned an MBA from the University of Arizona and a Bachelor of Science degree in Finance from the University of Illinois. He has been a Partner with Juniper Consulting Group, Inc. (Junicon) since 2002

    Stephan Eichholz

    Stephan Eichholz
    Advisory Board Member

    Stephan is a Europe-based marketing research and consulting veteran with nearly 20 years experience in healthcare markets and an extensive record of successful on-site project execution throughout Europe and the Americas. Stephan has particular strength in medical technology concept and prototype evaluations and market opportunity assessments for new business development initiatives
    Click here for more information
  • Stephan studied Economics, Political Science and Languages at Mainz University in Germany. He is fluent in German, English, Spanish and French
  • He began his career in healthcare market research and strategy consulting in 1997 in the Frankfurt office of The Martec Group, a US-based consultancy
  • Due to his language and analytical skills, Stephan covered a wide range of geographies and topics, working on site in North America and Latin America as well as Europe
  • Stephan managed a broad range of project topics and types across the healthcare spectrum for a range of international clients. Stephan became a partner in the firm in 2000
  • In 2002, he set up the European operations of Junicon, joining Rob Claar and Jeff Cocagne as a founding partner of the firm. Stephan has led Junicon Europe to continual growth in size and stature over its 10-year history

  • Dave Taggart

    Dave Taggart
    Advisory Board Member

    Dave has a broad range of experience in medical device, diagnostics, pharma/biotech and life sciences consulting through positions with Datamonitor, Integral Inc. and Analysis Group. His consulting engagements have included business strategy, licensing and acquisition, pipeline valuation, and new product development. In more than 500 projects, he has worked with large and small entities, from new start-ups to the largest global healthcare companies and national governments. Dave has been a Partner with Juniper Consulting Group, Inc. (Junicon) since 2010
    Click here for more information
  • A common theme of much of Dave's consulting practice is the identification, demonstration and communication of value in healthcare products. Much of this practice focuses on finding and articulating winning value propositions for new innovations through customer insight
  • Dave also leads a team of epidemiology and health economics professionals to conduct powerful clinical and health economic analyses, and a collateral development team to build winning marketing materials for innovative new products. His teams have generated physical and desktop/tablet based marketing tools in use in a number of global healthcare organizations
  • Originally from the UK, Dave is based in California, and serves US, European and Asian clients. He has a bachelor's degree from the University of Oxford, and a Master's Degree from the London School of Economics. Dave has been a Partner with Juniper Consulting Group (Junicon) since 2010

  • Steve Engen

    Steve Engen
    Advisory Board Member

    Former head of Shire Japan KK operations

    Mr. Engen served as CEO of Solasia Pharma KK from 2007 until 2012, where he was responsible for acquiring and developing the company’s oncology assets in Asia, and establishing operations in Japan and China. Prior to joining Solasia, Mr. Engen was President of Mundipharma KK, the Japan operation of the Purdue Pharma/Mundipharma Group, from 1998 to 2007. During this time, Mr. Engen oversaw Japan clinical development of a new product for chronic pain and managed the co-promotion collaboration with Shionogi & Co., Ltd. in the field of cancer pain

    Michael LoPresti

    Michael LoPresti
    Advisory Board Member

    Michael LoPresti is President of Junicon K.K. - the Japan office of the Juniper Consulting Group. While Junicon provides a broad range of healthcare marketing research and consulting services, Michael specializes in market access and pricing and reimbursement issues. He has supported numerous pharmaceutical and medical device companies with navigating the unique pricing and reimbursement environment in Japan
    Click here for more information
  • Michael moved to Japan in 2002 after completing two graduate degrees covering health economics and demography
  • He has since held senior roles at several healthcare marketing research and consulting companies in Japan. He continues to support overseas pharmaceutical and medical device companies with developing market entry strategies for Japan and Japanese healthcare companies with their assessment of overseas markets
  • Michael is also an expert on healthcare policy issues in Japan such as the funding of treatments for rare diseases, alternative access programs for high medical need treatments, and orphan drug designation
  • He has published several papers on the pricing of novel drugs in Japan and is the coauthor of a comprehensive 80-page report on the pricing of medical devices, diagnostics, and equipment in Japan
  • Michael is fluent in written and spoken Japanese

  • PREV


    Message from CEO
    Vision, Mission, Values